Hexarelin
Category 1Also known as: Examorelin, His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
Growth Hormone SecretagogueLast reviewed: April 28, 2026
A synthetic hexapeptide growth hormone secretagogue and one of the most potent GH-releasing peptides known. Stimulates GH release more strongly than most other GHS peptides, but also has significant effects on cortisol and prolactin.
Mechanism of Action
Binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, triggering strong GH release. Also has direct cardioprotective effects independent of GH, including protection against ischemia-reperfusion injury. Activates the CD36 receptor in cardiac tissue.
Common Uses
- Growth hormone optimization
- Muscle mass and strength
- Fat loss
- Cardiac protection (emerging research)
- Recovery from injury
Known Risks
- Significant cortisol and prolactin elevation (more than Ipamorelin)
- Water retention
- Increased appetite
- Desensitization with prolonged use
- Limited long-term human safety data
Regulatory Status
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
100–200 mcg
Frequency
2–3x daily
Cycle Length
4–8 weeks, then 4 weeks off (desensitization risk)
More potent than Ipamorelin but also more cortisol/prolactin elevation. Cycle off regularly to prevent receptor desensitization. Often preferred for short aggressive GH pulses rather than long-term protocols.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.